AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.
Wang S, Qiu Z, Hou Y, Deng X, Xu W, Zheng T, Wu P, Xie S, Bian W, Zhang C, Sun Z, Liu K, Shan C, Lin A, Jiang S, Xie Y, Zhou Q, Lu L, Huang J, Li X. · 2021
Read AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. by Wang S, Qiu Z, Hou Y, Deng X, Xu W, Zheng T, Wu P, Xie S, Bian W, Zhang C, Sun Z, Liu K, Shan C, Lin A, Jiang S, Xie Y, Zhou Q, Lu L, Huang J, Li X. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7791157.txt.
Introduction
Wang and co-authors identify AXL as a candidate second receptor for SARS-CoV-2. The virus is known to enter cells through ACE2. Yet ACE2 levels are very low in the airways. Other entry helpers may exist.
AXL bound directly to the front part of the viral spike protein. Adding AXL to lab cells let the virus in as well as ACE2 did. Removing AXL cut infection in lung cell lines sharply. It also cut infection in primary human lung cells. A soluble form of AXL blocked infection. In fluid from COVID-19 patient lungs, AXL levels matched viral spike levels. The authors argue AXL helps the virus infect the human airway.
Catalog record
| CREATOR | Wang S, Qiu Z, Hou Y, Deng X, Xu W, Zheng T, Wu P, Xie S, Bian W, Zhang C, Sun Z, Liu K, Shan C, Lin A, Jiang S, Xie Y, Zhou Q, Lu L, Huang J, Li X. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells By Shuai Wang, Zongyang Qiu, Yingnan Hou, Xiya Deng, Wei Xu, Tingting Zheng, Peihan Wu, Shaofang Xie, Weixiang Bian, Chong Zhang, Zewei Sun, Kunpeng Liu Published in: Cell Research DOI: 10.1038/s41422-020-00460-y ABSTRACT The current coronavirus disease 2019 (COVID-19) pandemic presents a global public health challenge. The viral pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to the host receptor ACE2 through its spike (S) glycoprotein, which mediates membrane fusion and viral entry. Although the role of ACE2 as a receptor for SARS-CoV-2 is clear, studies have shown that ACE2 expression is extremely low in various human tissues, especially in the respiratory tract. Thus, other host receptors and/or co-receptors that promote the entry of SARS-CoV-2 into cells of the respiratory system may exist. In this study, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S. Using both a SARS-CoV-2 virus pseudotype and authentic SARS-CoV-2, we found that overexpression of AXL in HEK293T cells promotes SARS-CoV-2 entry as efficiently as overexpression of ACE2, while knocking out AXL significantly reduces SARS-CoV-2 infection in H1299 pulmonary cells and in human primary lung epithelial cells. Soluble human recombinant AXL blocks SARS-CoV-2 infection in cells expressing high levels of AXL. The AXL expression level is well correlated with SARS-CoV-2 S level in bronchoalveolar lavage fluid cells from COVID-19 patients. Taken together, our findings suggest that AXL is a novel candidate receptor for SARS-CoV-2 which may play an important role in promoting viral infection of the human respiratory system and indicate that it is a potential target for future clinical intervention strategies. INTRODUCTION Coronavirus disease 2019 (COVID-19) has caused a global pandemic since December 2019 and presents a global public health threat. The causative viral pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly contagious enveloped positive-strand RNA virus1 that causes upper respiratory diseases, fever and severe pneumonia in humans.1,2 SARS-CoV-2 belongs to the β coronavirus genus. Other members of this genus include severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV), which caused outbreaks in 2003 and 2012, respectively, though on a much smaller scale.3,4 SARS-CoV-2 preferentially infects cells of the respiratory tract5 but has been detected in almost all human organs, including the lungs, pharynx, heart, liver, brain, kidneys and digestive system organs.6–8 Coronaviruses bind to host receptors through their spike (S) glycoproteins, which mediate membrane fusion and viral entry.9 The S protein is cleaved into the N-terminal S1 subunit and C-terminal S2 subunit by the host proteases Transmembrane protease serine 2 (TMPRSS2) and FURIN (Fig. 1a).10 SARS-CoV-2 shares 79.5% genetic identity with SARS-CoV, and studies have shown that ACE2, a cellular receptor for SARS-CoV,11 also binds SARS-CoV-2 S and serves as the entry point for SARS-CoV-2 (Fig. 1a).1,12 Although SARS-CoV-2 infection largely manifests with respiratory system symptoms, single-cell sequencing data indicate that overall ACE2 expression is low in various human tissues, especially pulmonary and bronchial tissues.13,14 A recently published single-cell mRNA sequencing dataset of 232,905 single cells from major adult organs15 revealed that ACE2 is specifically expressed in the kidneys and digestive system but rarely in organs such as the lungs and trachea (Supplementary information, Fig. S1a, b). The complex structures formed by binding between ACE2 and the receptor binding domain (RBD) of SARS-CoV-2 S have been resolved.16,17 However, recent studies have identified many neutralizing human antibodies that bind to SARS-CoV-2 S but do not bind the RBD.18,19 These results indicate that other important host receptors and/or co-receptors might exist that bind to different domain(s) of SARS-CoV-2 S and promote the entry of SARS-CoV-2 into cells of the respiratory system.Fig. 1ACE2 expression is low in the human lungs and trachea.a Schematic of SARS-CoV-2 virion surface S-mediated receptor recognition and membrane fusion. During viral infection, the trimeric S protein is cleaved into S1 and S2 subunits, and the S1 subunits are released during the transition to the post-fusion conformation. The RBD on S1 directly binds to ACE2, while S2 is responsible for membrane fusion. Overview of the human cell landscape at the single-cell level in lung (b) and tracheal cells (e). Abp cell, alveolar bipotent progenitor cell; DC, dendritic cell; EC, endothelial cell; EpC, epithelial cell; MC, macrophages; NK, natural killer cell; SMC, smooth muscle cell. ACE2 expression levels in pulmonary (c, d) and bronchial cells (f, g) were evaluated using the human cell landscape at the single-cell level. Gene expression for each cell type was visualized using tSNE (c, f) and violin plots (d, g). h Eleven lung, liver, kidney, stomach, and neural cell lines were infected with the GFP-labeled SARS-CoV-2 pseudotype. The infection efficiency was evaluated using microscopy images taken at 24 h post infection. The scale bar indicates 250 μm. BF, bright field. The data shown are representative results from three independent experiments (n = 3). Using tandem affinity purification (TAP)-mass spectrometry (MS) to analyze protein complexes interacting with SARS-CoV-2 S in pulmonary and bronchial cells, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with SARS-CoV-2 S. In HEK293T cells, AXL overexpression promoted viral entry as efficiently as ACE2 overexpression. Downregulating AXL, but not ACE2, significantly reduced infection of pulmonary cells by SARS-CoV-2. Soluble human recombinant AXL, but not ACE2, blocked SARS-CoV-2 infection in cells expressing high levels of AXL. Taken together, our results suggest AXL as a novel host receptor that promotes SARS-CoV-2 entry into human cells. RESULTS Identification of SARS-CoV-2 S candidate receptors in H1299 and BEAS-2B cells We analyzed the expression levels of ACE2 using a recently published single-cell mRNA sequencing dataset of 232,905 single cells from major adult human organs (all from non-SARS-CoV-2-infected samples)15 and found that ACE2 was specifically expressed in the jejunum (426/3075 cells), duodenum (95/2305 cells) and kidneys (681/20,053 cells) but rarely in organs such as the lungs (16/17,628 cells) and trachea (20/9521 cells) (Fig. 1b–g; Supplementary information, Table S1). To identify additional candidate receptors and/or co-receptors for SARS-CoV-2, we first assessed which of the following cell lines were vulnerable to infection: the human kidney-derived cell line HEK293T; the lung-derived cell lines NCI-H1299 (H1299), NCI-H460, NCI-H292, and CALU-3; the bronchus-derived cell line BEAS-2B; the stomach-derived cell line HGC-27; the liver-derived cell lines HepG2 and HL7702; the breast-derived cell line MDA-MB-231; and the neuron-derived cell line SH-SY5Y (Fig. 1h). The SARS-CoV-2 virus pseudotype successfully infected lung alveolar epithelial-like H1299 cells, immortalized normal bronchus BEAS-2B cells, immortalized liver carcinoma HepG2 cells and normal liver HL7702 cells (Fig. 1h). Thus, we used H1299 and BEAS-2B cells for the following studies to identify putative additional receptors or co-receptors responsible for SARS-CoV-2 infection of pulmonary and bronchial cells. To find the best strategy to mimic the expression and cleavage of SARS-CoV-2 S on the host cell membrane, we overexpressed full-length SARS-CoV-2 S, SARS-CoV-2 S RBD, or SARS-CoV-2 S S1+S2 in these cells or added recombinant full-length SARS-CoV-2 S or SARS-CoV-2 S RBD to the cells. Only cells overexpressing full-length SARS-CoV-2 S showed strong membrane localization of the S protein (Supplementary information, Fig. S2a). Moreover, full-length SARS-CoV-2 S was successfully cleaved in H1299 and BEAS-2B cells, generating fragments with sizes similar to those of S1-cleaved